FindTrial
Sign In

Fibrinolytic-Associated Urticaria, Angioedema, and Type I Hypersensitivity Reactions from Various Indications

Fibrinolytic-Associated Urticaria, Angioedema, and Type I Hypersensitivity Reactions from Various Indications

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20190607003
Enrollment
Unknown
Registered
2019-06-07
Start date
2019-01-21
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All fibrinolytic agents either non&#45

Interventions

Urticaria was characterized by the appearance of pruritic&#44
erythematous papules or plaques&#44
with superficial swelling of the dermis. Angioedema was defined as clinically manifestation with bouts of asymmetric nondependent swelling involving cutaneous or mucosal surfaces&#44
for instance&#44
the face&#44
lips&#44
tongue&#44
oropharynx&#44
extremities&#44
or genitalia.1 In this study&#44
type I hypersensitivity reactions covered anaphylactic reactions (anaphylaxis and anaphylactic shock)&#44
hemodynamic (hypotension) and respiratory complications (e.g. bronchospasm&#44
wheezes&#44
dyspnea&#44
chest discomfort). Anaphylaxis was confirmed when any one of the criteria from National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network was fulfilled
Other
streptokinase&#44
tenecteplase&#44
tissue plasminogen activator

Sponsors

No sponsor
Lead Sponsor
No sponsor
Collaborator

Eligibility

Sex/Gender
All
Age
18 Years to 89 Years

Inclusion criteria

Inclusion criteria: Medical records, either electronic or paper, were reviewed and collected clinical characteristic including gender, age, body weight, baseline systolic and diastolic blood pressure, co-morbidities, medication prior to admission, history of medication allergy, history of prior streptokinase exposure, indications, dosage and administration, premedication strategy, concomitant medications, echocardiogram, electrocardiogram, computed tomography scan, NIHSS score, vital signs, laboratory data. We especially reviewed the medical records of all cases of suspected urticaria, angioedema, and type I hypersensitivity reactions. The following data were extracted: first and last date of fibrinolytic agent usage, onset of suspected reactions, management and clinical outcomes.

Exclusion criteria

Exclusion criteria: No exclusion criteria

Design outcomes

Primary

MeasureTime frame
urticaria, angioedema, and type I hypersensitivity reactions associated with fibrinolytic agents 10 years Retrospective search over a 10-year period, from January 2008, through December 2017—

Secondary

MeasureTime frame
No secondary outcome No No—

Countries

THAILAND

Contacts

Public ContactPORNWALAI BOONMUANG

Faculty of Pharmacy, Silpakorn University

pharm_md@hotmail.com095-6519822

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026